Targeted pathways in breast cancer: Molecular and protein markers guiding therapeutic decisions

Current Molecular Pharmacology

Volumn 7, Issue 1, 2014, Pages 4-21

  Kourea, Helen P ^a   Zolota, Vassiliki ^a   Scopa, Chrisoula D ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Biomarkers; Breast carcinoma; ER PgR; HER2; Ki67; miRNAs; Molecular signatures; Prognostic predictive; TILs

Indexed keywords

CELL CYCLE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; VASCULOTROPIN; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL DECISION MAKING; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC STABILITY; HISTONE ACETYLATION; HISTONE METHYLATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIGENE FAMILY; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; TRANSLATIONAL RESEARCH; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; BREAST NEOPLASMS; FEMALE; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; EPIGENOMICS; FEMALE; HUMANS; KI-67 ANTIGEN; MICRORNAS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84921915735     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/187446720701150105170830     Document Type: Article

References (176)

1. Berry, D.A.; Cronin, K.A.; Plevritis, S.K.; Fryback, D.G.; Clarke, L.; Zelen, M.; Mandelblatt, J.S.; Yakoviev, A.Y.; Habemma, J.D.; Feuer, E.J. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med., 2005, 353, 1784-1792.
2. Perou, C.M.; Sørlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; Fluge, O.; Pergamenschikov, A.; Williams, C.; Zhu, S.X.; Lønning, P.E.; Børresen-Dale, A.L.; Brown, P.O.; Botstein, D. Molecular portraits of human breast tumours. Nature, 2000, 406, 747-752.
3. Sorlie, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Thorsen, T.; Quist, H.; Matese, J.C.; Brown, P.O.; Botstein, D.; Lønning, P.E.; Børresen-Dale, A.L. expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS, 2001, 98, 10869-10874.
4. Edge, S.B.; Byrd, D.R.; Compton, C.C.; Fritz, A.G.; Greene, F.L.; Trotti, A. III, Eds; AJCC Cancer Staging Handbook Seventh edition, Springer: New York Dordrecht Heidelberg London, 2010.
5. National Comprehensive Cancer Network clinical practice guidelines in oncology: Breast Cancer, version 3. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [Accessed August 25, 2014].
6. Ravdin, P.M.; Siminoff, L.A.; Davis, G.J.; Mercer, M.B.; Hewlett, J.; Gerson, N.; Parker, H.L. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol., 2001, 19, 980-991.
7. Wishart, G.C.; Bajdik, C.D.; Dicks, E.; Provenzano, E.; Schmidt, M.K.; Sherman, M.; Greenberg, D.C.; Green, A.R.; Gelmon, K.A.; Kosma, V.M.; Olson, J.E.; Beckmann, M.W.; Winqvist, R.; Cross, S.S.; Severi, G.; Huntsman, D.; Pylkäs, K.; Ellis, I.; Nielsen, T.O.; Giles, G.; Blomqvist, C.; Fasching, P.A.; Couch, F.J.; Rakha, E.; Foulkes, W.D.; Blows, F.M.; Bégin, L.R.; van't Veer, L.J.; Southey, M.; Nevanlinna, H.; Mannermaa, A.; Cox, A.; Cheang, M.; Baglietto, L.; Caldas, C.; Garcia-Closas, M.; Pharoah, P.D. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br. J. Cancer, 2012, 107, 800-807.
8. Mehta, R.; Jain, R.K.; Badve, S. Personalized medicine: The road ahead. Clin. Breast Cancer, 2011, 11, 20-26.
9. Reis-Filho, J.S.; Pusztai, L.; Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet., 2011, 378, 1812-1823
10. Goldhirsch, A.; Wood, W.C.; Coates, A.S.; Gelber, R.D.; Thürlimann, B.; Senn, H.J.; Panel members. Strategies for subtypes-- dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol., 2011, 22, 1736-1747.
11. Goldhirsch, A.; Winer, E.P.; Coates, A.S.; Gelber, R.D.; Piccart- Gebhart, M.; Thurlimann, B.; Senn, H.J. Personalizing the treatment of women with breast cancer. Ann. Oncol., 2013, 24, 2206- 2223.
12. Harbeck, N.; Thomssen, C.; Gnant, M. St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care (Basel), 2013, 8, 102-109.
13. Acconcia, F.; Kumar, R. Signalling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett., 2006, 238, 1-14.
14. May F.E. Novel drugs that target the estrogen-related receptor-α: their therapeutic potential in breast cancer. Cancer Manag. Res., 2014, 6, 225-252.
15. Patterni, I.; Granchi, C.; Katzenellenbogen, J.A.; Minutolo, F. Estrogen receptors α (ERα) and beta (β): Subtype-selective ligands and clinical potential. Steroids, 2014 (in press).
16. Hammond, M.E.; Hayes, D.F.; Dowsett, M.; Allred, D.C.; Hagerty, K.L.; Badve, S.; Fitzgibbons, P.L.; Francis, G.; Goldstein, N.S.; Hayes, M.; Hicks, D.G.; Lester, S.; Love R.; Mangu, P.B.; McShane, L.; Miller, K.; Osborne, C.K.; Paik, S.; Perlmutter, J.; Rhodes, A.; Sasano, H.; Schwartz, J.N.; Sweep, F.C.; Taube, S.; Torlakovic, E.E.; Valenstein, P.; Viale, G.; Visscher, D.; Wheeler, T.; Williams, R.B.; Wittliff, J.L.; Wolff, A.C. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med., 2010, 134, e48-e72.
17. Hammond, M.E.; Hayes, D.F.; Dowsett, M.; Allred D.C.; Hagerty, K.L.; Badve, S.; Fitzgibbons, P.L.; Francis, G.; Goldstein, N.S.; Hayes, M.; Hicks, D.G.; Lester, S.; Love, R.; Mangu, P.B.; McShane, L.; Miller, K.; Osborne, C.K.; Paik, S.; Perlmutter, J.; Rhodes, A.; Sasano, H.; Schwartz, J.N.; Sweep, F.C.; Taube, S.; Torlakovic, E.E.; Valenstein, P.; Viale, G.; Visscher, D.; Wheeler, T.; Williams, R.B.; Wittliff, J.L.; Wolff, A.C. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol., 2010, 28, 2784-2795.
18. Anderson, W.F.; Chatterjee, N.; Ershler, W.B.; Brawley, O.W. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res. Treat., 2002, 76, 27-36.
19. Geyer, F.C.; Rodrigues, D.N.; Weigelt, B.; Reiss-Filho, J.S. Molecular classification of estrogen receptor positive/luminal breast cancers. Adv. Anat. Pathol., 2012, 19, 39-53.
20. Mohamed, A.; Krajewski, K.; Cakar, B.; Ma, C.X. Targeted therapy for breast cancer. Am. J. Pathol., 2013, 183, 1096-1112.
21. Patani, N.; Martin, L.-A.; Dowsett, M. Biomarkers for the clinical management of breast cancer: International perspective. Int. J. Cancer, 2013, 133, 1-13.
22. Burstein, H.J.; Temin, S.; Anderson H.; Buchholz, T.A.;. Davidson, N.E.; Gelmon, K.E.; Giordano, S.H.; Hudis, C.A.; Rowden, D.; Solky, A.J.; Stearns, V.; Winer E.P.; Griggs, J.J. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J. Clin. Oncol., 2014, 32, 1-16.
23. Shou, J.; Massarweh, S.; Osborne, C.K.; Wakeling, A.E.; Ali, S.; Weiss, H.; Schiff, R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2- positive breast cancer. J. Natl. Cancer Inst., 2004, 96, 926-935.
24. Guiliano, M.; Schiff, R.; Osborne, C.K.; Trivedi, M.V. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. The Breast, 2011, 20, S42-S49.
25. Davies, C.; Godwin, J.; Gray, R.; Clarke, M.; Cutter, D.; Darby, S.; McGale, P.; Pan, HC.; Taylor, C.; Wang, Y.C.; Dowsett M.; Ingle, J.; Peto, R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level metaanalysis of randomised trials. Lancet, 2011, 378, 771-784.
26. Dunnwald, L.K.; Rossing, M.A.; Li, C.I. Hormone receptor status, tumor characteristics and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res., 2007, 9, R6.
27. Prat, A.; Cheang, M.C.; Martín, M.; Parker, J.S.; Carrasco, E.; Caballero, R.; Tyldesley, S.; Gelmon, K.; Bernard, P.S.; Nielsen, T.O.; Perou, C.M. Prognostic significance of progesterone receptor- positive tumor cells within immunohistochemically defined luminal A breast cancer. J. Clin. Oncol., 2012, 31, 203-209.
28. Rexer, B.N.; Arteaga, C.L. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit. Rev. Oncogen., 2012, 17, 1-16.
29. Freudenberg, J.A.; Wang, Q.; Katsumata, M.; Drebin, J.; Nagatomo, I.; Greene, M.I. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp. Molec. Pathol., 2009, 87, 1-11.
30. Marmor, M.D.; Skaria, K.B.; Yarden, Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys., 2004, 58, 903-913.
31. Yamamoto, T.; Ikawa, S.; Akiyama, T.; Semba, K.; Nomura, N.; Miyajima, N.; Saito, T.; Toyoshima, K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986, 319, 230-234.
32. Coulson, S.G.; Kumar, V.S.; Manifold, I.M.; Hatton, M.Q.; Ramakrishnan, S.; Dunn, K.S.; Purohit, O.P.; Bridgewater, C.; Coleman, R.E. Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients? Clin. Oncol. (R. Coll.Radiol.), 2010, 22, 289-293
33. Wolff, A.C.; Hammond, E.H.; Hicks, D.G.; Dowsett, M.; McSnane, L.M.; Allison, K.H.; Allred, D.C.; Bartlett, J.M.; Bilous, M.; Fitzgibbons, P.; Hanna, W.; Jenkins, R.B.; Mangu, P.B.; Paik, S.; Perez, E.A.; Press, M.F.; Spears, P.A.; Vance, G.H.; Viale, G.; Hayes, D.F. Recommendations for human epidermal growth factor receptor testing in breast cancer: American Society of Clinical Oncology/ College of American Pathologists clinical practice guideline update. J. Clin. Oncol., 2013, 31, 3997-4014.
34. Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Sommerfield, M.R.; Hayes, D.F.; Bast, R.C. Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol., 2007, 25, 5287-5312.
35. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature, 2012, 490, 61-70.
36. Romond, E.H.; Perez, E.A.; Bryant, J.; Suman, V.J.; Geyer, C.E. Jr; Davidson, N.E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P.A.; Swain, S.M.; Pisansky, T.M.; Fehrenbacher, L.; Kutteh, L.A.; Vogel, V.G.; Visscher, D.W.; Yothers, G.; Jenkins, R.B.; Brown, A.M.; Dakhil, S.R.; Mamounas, E.P.; Lingle, W.L.; Klein, P.M.; Ingle, J.N.; Wolmark, N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med., 2005, 353, 1673-1684.
37. Smith, I.; Procter, M.; Gelber, R.D.; Guillaume, S.; Feyereislova, A.; Dowsett, M.; Goldhirsch, A.; Untch, M.; Mariani, G.; Baselga, J.; Kaufmann, M.; Cameron, D.; Bell, R.; Bergh, J.; Coleman, R.; Wardley, A.; Harbeck, N.; Lopez, R.I.; Mallmann, P.; Gelmon, K.; Wilcken, N.; Wist, E.; Sánchez Rovira, P.; Piccart-Gebhart, M.J;. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 2007, 369, 29-36.
38. Dowsett, M.; Procter, M.; McCaskill-Stevens, W.; de Azambuja, E.; Dafni, U.; Rueschoff, J.; Jordan, B.; Dolci, S.; Abramovitz, M.; Stoss, O.; Viale, G.; Gelber, R.D.; Piccart-Gebhart, M.; Leyland- Jones, B. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J. Clin. Oncol., 2009, 27, 2962-2969.
39. Arnould, L. Gelly M.; Penault-Llorca, F.; Benoit, L.; Bonnetain, F.; Migeon, C.; Cabaret, V.; Fermeaux, V.; Bertheau, P.; Garnier, J.; Jeannin, J.F.; Coudert, B. Trastuzumab-based treatment of HER2- positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer, 2006, 94, 259-267.
40. Cuello, M.; Ettenberg, S.A.; Clark, A.S.; Keane, M.M.; Posner, R.H.; Nau, M.M.; Dennis, P.A.; Lipkowitz, S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res., 2001, 61, 4892-4900.
41. Junttila, T.T.; Akita, R.W.; Parsons, K.; Fields, C.; Lewis Phillips, G.D.; Friedman, L.S.; Sampath, D.; Sliwkowski, M.X. Ligandindependent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell, 2009, 15, 429-440.
42. Molina, M.A.; Codony-Servat, J.; Albanell, J.; Rojo, F.; Arribas, J.; Baselga, J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res., 2001, 61, 4744- 4749.
43. Scheuer W.; Friess, T.; Burtscher, H.; Bossenmaier, B.; Endl, J.; Hasmann, M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res., 2009, 69, 9330-9336.
44. Baselga, J.; Cortés, J.; Kim, S-B.; Im S-A.; Hegg, R.; Im, Y-H.; Roman, L.; Pedrini, J.L.; Pienkowski, T.; Knott, A.; Clark, E.; Benyunes, M.C.; Ross, G.; Swain, S.M. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med., 2012, 366, 109-119.
45. Verma, S.; Miles, D.; Gianni, L.; Krop, I.E.; Welslau, M.; Baselga, J.; Pegram, M.; Oh, D.Y.; Diéras, V.; Guardino, E.; Fang, L.; Lu, M.W.; Olsen, S.; Blackwell, K.; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med., 2012, 367, 1783-1791.
46. Gennari, A.; Sormani, M.P.; Pronzato, P.; Puntoni, M.; Colozza, M.; Pfeffer, U.; Bruzzi, P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J. Natl. Cancer Inst., 2008, 100, 14-20.
47. Konecny, G.E.; Thomssen, C.; Lück, H.J.; Untch, M.; Wang, H.J.; Kuhn, W.; Eidtmann, H.; du Bois, A.; Olbricht, S.; Steinfeld, D.; Möbus, V.; von Minckwitz, G.; Dandekar, S.; Ramos, L.; Pauletti, G.; Pegram, MD.; Jänicke, F.; Slamon, D.J. Her2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J. Natl. Cancer Inst., 2004, 96, 1141-1151.
48. De, P.; Hasmann, M.; Leyland-Jones, B. Molecular determinants of trastuzumab efficacy: What is their clinical relevance? Cancer Treat. Rev., 2013, 39, 925-934.
49. Loi, S.; Michiels, S.; Salgado, R.; Sirtaine, N.; Jose, V.; Fumagalli, D.; Kellokumpu-Lehtinen, PL.; Bono, P.; Kataja, V.; Desmedt, C.; Piccart, M.J.;, Loibl, S.; Denkert, C.; Smyth, M.J.; Joensuu, H.; Sotiriou, C. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Ocol., 2014, 25, 1544-1550.
50. Engebraaten, O.; Vollan, H.K.; Børresen-Dale, A.L. Triplenegative breast cancer and the need for new therapeutic targets. Am. J. Pathol., 2013, 183, 1064-1074.
51. Lehmann, B.D.; Bauer, J.A.; Chen, X.; Sanders, M.E.; Chakravarthy, A.B.; Shyr, Y.; Pietenpol, J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest., 2011, 121, 2750- 67
52. Montagna, E.; Maisonneuve, P.; Rotmensz, N.; Cancello, G.; Iorfida, M.; Balduzzi, A; Galimberti, V.; Veronesi, P.; Luini, A.; Pruneri, G.; Bottiglieri, L.; Mastropasqua, M.G.; Goldhirsch, A.; Viale, G.; Colleoni, M. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin. Breast Cancer, 2013, 13, 31-39.
53. Perou, C.M. Molecular stratification of triple-negative breast cancers. Oncologist, 2011, 16, 61-70.
54. Curtis, C.; Shah, S.P.; Chin, S.F.; Turashvili, G.; Rueda, O.M.; Dunning, M.J.; Speed, D.; Lynch, A.G.; Samarajiwa, S.; Yuan, Y.; Gräf, S.; Ha, G.; Haffari, G.; Bashashati, A.; Russell, R.; McKinney, S.; METABRIC Group; Langerød, A.; Green, A.; Provenzano, E.; Wishart, G.; Pinder, S.; Watson, P.; Markowetz, F.; Murphy, L.; Ellis, I.; Purushotham, A.; Børresen-Dale, A.L.; Brenton, J.D.; Tavaré, S.; Caldas, C.; Aparicio, S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 2012, 486, 346-352.
55. Bayraktar. S.; Glück, S. Molecularly targeted therapies for metastatic triple- negative breast cancer. Breast Cancer Res. Treat., 2013, 138, 21-35.
56. Harbeck, N.; Sotlar, K.; Wuerstlein, R.; Doisneau-Sixou, S. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. Cancer Treat. Rev., 2014, 40, 434- 444.
57. Hu, Z.; Fan. C.; Oh, D.S.; Marron, J.S.; He, X.; Qaqish, B.F.; Livasy, C.; Carey, L.A.; Reynolds, E.; Dressler, L.; Nobel, A.; Parker, J.; Ewend, M.G.; Sawyer, L.R.; Wu, J.; Liu, Y.; Nanda, R.; Tretiakova, M.; Ruiz Orrico, A.; Dreher, D.; Palazzo, J.P.; Perreard, L.; Nelson, E.; Mone, M.; Hansen, H.; Mullins, M.; Quackenbush, J.F.; Ellis, M.J.; Olopade, O.I.; Bernard, P.S.; Perou, C.M. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 2006, 7, 96.
58. Kennecke, H.; Yerushalmi, R.; Woods, R.; Cheang, M.C.U.; Voduc, D.; Speers, C.H.; Nielsen, T.O.; Gelmon, K. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol., 2010, 28, 3271- 3277.
59. Voduc, K.D.; Cheang, M.C.; Tyldesley, S.; Gelmon, K.; Nielsen, T.O.; Kennecke, H. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol., 2010, 28, 1684-1691.
60. De Ronde, J.J.; Hannemann, J.; Halfwerk. H.; Mulder, L.; Straver, M.E.; Vrancken Peeters, M.J.; Wesseling, J.; van de Vijver, M.; Wessels, L.F.; Rodenhuis, S. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res. Treat., 2010, 119, 119-126.
61. Herschkowitz, J.I.; Simin, K.; Weigman, V.J.; Mikaelian, I.; Usary, J.; Hu, Z.; Rasmussen, K.E.; Jones, L.P.; Assefnia, S.; Chandrasekharan, S.; Backlund, M.G.; Yin, Y.; Khramtsov, A.I.; Bastein, R.; Quackenbush, J.; Glazer, R.I.; Brown, P.H.; Green, J.E.; Kopelovich, L.; Furth, P.A.; Palazzo, J.P.; Olopade, O.I.; Bernard, P.S.; Churchill, G.A.; Van Dyke, T.; Perou CM. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol., 2007, 8, R76.
62. Prat, A.; Parker, J.S.; Karginova, O.; Fan, C.; Livasy, C.; Herschkowitz, J.I.; He, X.; Perou, C.M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res., 2010, 12, R68.
63. Den Hollander, P.; Savage, M.I.; Brown, P.H. Targeted therapy for breast cancer prevention. Front Oncol., 2013, 3, 250.
64. Gerdes, J.; Schwab, U.; Lemke, H.; Stein, H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer, 1983, 31, 13-20.
65. Sotiriou, C.; Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med., 2009, 360, 790-800.
66. Cheang, M.C.U.; Chia, S.K.; Voduc, D.; Gao, D.; Leung, S.; Snider, J.; Watson, M.; Davies, S.; Bernard, P.S.; Parker, J.S.; Perou, C.M.; Ellis, M.J.; Nielsen, T.O. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst., 2009, 101, 736-750.
67. Goldhirsch, A.; Ingle, J.N.; Gelber, R.D.; Coates, A.S.; Thürlimann, B.; Senn, H.J.; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol., 2009, 8, 1319-1329.
68. Yerushalmi, R.; Woods, R.; Ravdin, P,; Hayes, M.M.; Gelmon, K.A. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol., 2010, 11, 174-183.
69. Dowsett, M.; Nielsen, T.O.; A'Hern, R.; Bartlett, J.; Coombes, R.C.; Cuzick, J.; Ellis, M.; Henry, N.L.; Hugh, J.C.; Lively, T.; McShane, L.; Paik, S.; Penault-Llorca, F.; Prudkin, L.; Regan M.; Salter, J.; Sotiriou, C.; Smith, I.E.; Viale, G.; Zujewski, J.A.; Hayes D.F.; International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl. Cancer Inst., 2011, 103, 1656-1664.
70. Nitz, U.; Gluz, O.; Huober, J.; Kreipe, H.H.; Kates, R.E.; Hartmann A.; Erber, R.; Scholz, M.; Lisboa, B.; Mohrmann, S.; Möbus, V.; Augustin, D.; Hoffmann, G.; Weiss, E.; Böhmer, S.; Kreienberg, R.; Du Bois, A.; Sattler, D.; Thomssen, C.; Kiechle, M.; Jänicke, F.; Wallwiener, D.; Harbeck, N.; Kuhn, W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate- risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann. Oncol., 2014, doi: 10.1093/annonc/mdu186 (in press)
71. Ellis, M.J.; Tao, Y.; Luo, J.; A'Hern, R.; Evans, D.B.; Bhatnagar, A.S.; Chaudri Ross, H.A.; von Kameke, A.; Miller, W.R.; Smith, I.; Eiermann, W.; Dowsett, M. Outcome prediction for estrogen receptor- positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J. Natl. Cancer Inst., 2008, 100, 1380- 1388.
72. Cuzick, J.; Dowsett, M.; Pineda, S.; Wale, C.; Salter, J.; Quinn, E.; Zabaglo, L.; Mallon, E.; Green, A.R.; Ellis, I.O.; Howell, A.; Buzdar, A.U.; Forbes, J.F. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J. Clin. Oncol., 2011, 29, 4273-4278.
73. Sgroi, D.S.; Sestak, I.; Cuzick, J.; Zhang, Y.; Schnabel, C.A.; Schroeder, B.; Erlander, M.G.; Dunbier, A.; Sidhu, K.; Lopez- Knowles, E.; Goss, P.E.; Dowsett, M. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol., 2013, 14, 1067-1076.
74. Dowsett, M.; Sestak, I;. Lopez-Knowles, E.; Sidhu, K.; Dunbier, A.K.; Cowens, J.W.; Ferree, S.; Storhoff, J.; Schaper, C.; Cuzick, J. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J. Clin. Oncol., 2013, 31, 2783-2790.
75. Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F.; Walker, M.G.; Watson, D.; Park, T.; Hiller, W.; Fisher, E.R.; Wickerham, D.L.; Bryant, J.; Wolmark, N. A multigene assay to predict recurrence of tamoxifen-treated nodenegative breast cancer. N. Engl. J. Med., 2004, 351, 2817-2826.
76. Habel, L.A.; Shak, S.; Jacobs, M.K.; Capra, A.; Alexander, C.; Pho, M.; Baker, J.; Walker, M.; Watson, D.; Hackett, J.; Blick, N.T.; Greenberg, D.; Fehrenbacher, L.; Langholz, B.; Quesenberry, C.P. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res., 2006, 8, R25.
77. Sparano, J.A. TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer., 2006, 7, 347-350.
78. Albain, K.S.; Barlow, W.E.; Shak, S.; Hortobagyi, G.N.; Livingston, R.B.; Yeh, I.T.; Ravdin, P.; Bugarini, R.; Baehner, F.L.; Davidson, N.E.; Sledge, G.W.; Winer, E.P.; Hudis, C.; Ingle, J.N.; Perez, E.A.; Pritchard, K.I.; Shepherd, L.; Gralow, J.R.; Yoshizawa, C.; Allred, D.C.; Osborne, C.K.; Hayes, D.F. Breast Cancer Intergroup of North America Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol., 2010, 11, 55-65.
79. Dowsett, M.; Cuzick, J.; Wale, C.; Forbes, J.; Mallon, E.A.; Salter, J.; Quinn, E.; Dunbier, A.; Baum, M.; Buzdar, A.; Howell, A.; Bugarini, R.; Baehner, F.L.; Shak, S. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol., 2010, 28, 1829-1834.
80. Espinosa, E.; Vara, J.A.; Redondo, A.; Sanchez, J.J.; Hardisson, D.; Zamora, P.; Pastrana, F.G.; Cejas, P.; Martinez, B.; Suarez, A.; Calero, F.; Baron, M.G. Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J. Clin. Oncol, 2005, 23, 7278-7285.
81. Van de Vijer, M.J.; He, Y.D.; van't Veer, L.J.; Dai, H.; Hart, A.A.; Voskuil, D.W.; Schreiber, G.J.; Peterse, J.L.; Roberts, C.; Marton, M.J.; Parrish, M.; Atsma, D.; Witteveen, A.; Glas, A.; Delahaye, L.; van der Velde, T.; Bartelink, H.; Rodenhuis, S.; Rutgers, E.T.; Friend, S.H.; Bernards, R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 2002, 347, 1999- 2009.
82. Gluck, S.; De Snoo, F.; Peeters, J.; Somlo, G.; Storks-Sloots, L.; van't Veer, L.J. Response and long term outcomes after neoadjuvant chemotherapy: Pooled dataset of patients stratified by molecular subtypying by MammaPrint and BluePrint. J. Clin. Oncol., 2012, Abst 10597.
83. Rutgers, E.; Piccart-Gebhart, M.J.; Bogaerts, J.; Delaloge, S.; Veer, L.V.; Rubio, I.T.; Viale, G.; Thompson, A.M.; Passalacqua, R.; Nitz, U.; Vindevoghel, A.; Pierga, J.Y.; Ravdin, P.M.; Werutsky, G.; Cardoso, F. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur. J. Cancer., 2011, 47, 2742- 2749.
84. Nielsen, T.O.; Parker, J.S.; Leung, S.; Voduc, D.; Ebbert, M.; Vickery, T.; Davies, S.R.; Snider, J.; Stijleman, I.J.; Reed, J.; Cheang, M.C.; Mardis, E.R.; Perou, C.M.; Bernard, P.S.; Ellis, M.J. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res., 2010, 16, 5222-5232
85. Chia, S.K.; Bramwell, V.H.; Tu, D.; Shepherd, L.E.; Jiang, S.; Vickery, T.; Mardis, E.; Leung, S.; Ung, K.; Pritchard, K.I.; Parker, J.S.; Bernard, P.S.; Perou, C.M.; Ellis, M.J.; Nielsen, T.O. A 50- gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin. Cancer Res., 2012, 18, 4465-4472
86. Sotiriou, C.; Wirapati, P.; Loi, S.; Harris, A.; Fox. S.; Smads, J.; Nordgren, H.; Farmer, P.; Praz, V.; Haibe-Kains, B.; Desmedt, C.; Larsimont, D.; Cardoso, F.; Peterse, H.; Nuyten, D.; Buyse, M.; Van de Vijer, M.J.; Bergh, J.; Piccart, M.; Delorenzi, M. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst., 2006, 98, 262-272.
87. Toussaint, J.; Sieuwerts, A.M.; Haibe-Kains, B.; Desmedt, C.; Rouas, G.; Harris, A.L.; Larsimont, D.; Piccart, M.; Foekens, J.A.; Durbecq, V.; Sotiriou C. Improvements of the clinical applicability of the genomic grade index through a qrt-pcr test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics, 2009, 10, 424-436.
88. Metzger-Filho, O.; Michiels, S.; Bertucci, F.; Catteau, A.; Salgado, R.; Galant, C.; Fumagalli, D.; Singhal, S.K.; Desmedt, C.; Ignatiadis, M.; Haussy, S.; Finetti, P.; Birnbaum, D.; Saini, K.S.; Berlière, M.; Veys, I.; de Azambuja, E.; Bozovic, I.; Peyro-Saint- Paul, H.; Larsimont, D.; Piccart, M.; Sotiriou C. Genomic grade adds prognostic value in invasive lobular carcinoma. Ann. Oncol., 2013, 24, 377-384
89. Wang, Y.; Klijn, J.G.; Zhang, Y.; Sieuwerts, A.M.; Look, M.P.; Yang, F.; Talantov, D.; Timmermans, M.; Meijer-van Gelder, M.E.; Yu, J.; Jatkoe, T.; Berns, E.M.; Atkins, D.; Foekens, J.A. Gene-expression profiles to predict distant metastasis of lymphnode- negative primary breast cancer. Lancet, 2005, 365, 671-679.
90. Desmedt, C.; Piette, F.; Loi, S.; Wang, Y.; Lallemand, F.; Haibe- Kains, F.; Viale, G.; Delorenzi, M.; Zhang, Y.; d'Assignies, M.S.; Bergh, J.; Lidereau, R.; Ellis, P.; Harris, A.L.; Klijn, J.G.; Foekens, J.A.; Cardoso, F.; Piccart, M.J.; Buyse, M.; Sotirou, C. TRANSBIG consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer. Res., 2007, 13, 3207-3214.
91. Jerevall, P.L.; Ma, X.J.; Li, H.; Salunga, R.; Kesty, N.C.; Erlander, M.G.; Sgroi, D.C.; Holmlund, B.; Skoog, L.; Fornander, T.; Nordenskjöld, B.; Stål, O. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br. J. Cancer, 2011, 104, 1762-1769.
92. Zhang, Y.; Schnabel, C.A.; Schroeder, B.E.; Jerevall, P.L.; Jankowitz, R.C.; Fornander, T.; Stål, O.; Brufsky, A.M.; Sgroi, D.; Erlander, M.G. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and latedistant recurrence. Clin. Cancer Res., 2013, 19, 4196-4205.
93. de la Cruz-Merino, L.; Barco-Sánchez, A.; Hena Carrasco, F.; Nogales Fernández, E.; Vallejo Benítez, A.; Brugal Molina, J.; Martínez Peinado, A.; Grueso López, A.; Ruiz Borrego, M.; Codes Manuel de Villena, M.; Sánchez-Margalet, V.; Nieto-García, A.; Alba Conejo, E.; Casares Lagar, N.; Ibáñez Martínez, J. New insights into the role of the immune microenvironment in breast carcinoma. Clin. Dev. Immunol., 2013, 2013, 785317http://dx.doi.org/10.1155/2013/785317.
94. Demaria, S.; Volm, M.D.; Shapiro, R.L.; Yee, H.T.; Oratz, R.; Formenti, S.C.; Muggia, F.; Symmans, WF. Clin. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Cancer Res., 2001, 7, 3025-3030.
95. Lee, A.H.S.; Gillett, C.E.; Ryder, K.; Fentiman, I.S.; Miles, D.W.; Millis, R.R. Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathol., 2006, 48, 692-701.
96. Denkert, C.; Loibl, S.; Noske, A.; Roller, M.; Müller, B.M.; Komor, M.; Budczies, J.; Darb-Esfahani, S.; Kronenwett, R.; Hanusch, C.; von Törne, C.; Weichert, W.; Engels, K.; Solbach, C.; Schrader, I.; Dietel, M.; von Minckwitz, G. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol., 2010, 28, 105-113.
97. Loi, S.; Sirtaine, N.; Piette, F, Salgado, R.; Viale, G.; Van Eenoo, F.; Rouas, G.; Francis, P.; Crown, J.P.; Hitre, E.; de Azambuja, E.; Quinaux, E.; Di Leo, A.; Michiels, S.; Piccart, M.J.; Sotiriou, C. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in nodepositive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol., 2013, 31, 860-867.
98. Aaltomaa, S.; Lipponen, P.; Eskelinen, M.; Kosma, V.M.; Marin, S.; Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur. J. Cancer, 1992, 28A, 859-864.
99. Bianchini, G.; Gianni, L. The immune system and response to HER2-targeted treatment in breast cancer. The Lancet Oncol., 2014, 15, e58-e68.
100. Loi, S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology, 2013, 2, e24720.
101. Mahmoud, S.M.; Paish, E.C.; Powe, D.G.; Macmillan, R.D.; Grainge, M.J.; Lee, A.H.; Ellis, I.O.; Green, A.R. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol., 2011, 29, 1949-1955.
102. Ladoire, S.; Arnould, L.; Apetoh, L.; Coudert, B.; Martin, F.; Chauffert, B.; Fumoleau, P.; Ghiringhelli, F. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin. Cancer Res., 2008, 14, 2413-2420.
103. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell, 1997, 88, 323-331.
104. Nenutil, R.; Smardova, J.; Pavlova, S,l; Hanzelkova, Z.; Muller, P.; Fabian, P.; Hrstka, R.; Janotova, P.; Radina, M.; Lane, D.P.; Coates, P.J.; Vojtesek, B. Discriminating functional and nonfunctional p53 in human tumours by p53 and MDM2 immunohistochemistry. J. Pathol., 2005, 207, 251-259.
105. Fitzgibbons, P.L.; Page, D.L.; Weaver, D.; Thor A.D.; Allred, D.C.; Clark, G.M.; Ruby, S.G.; O'Malley, F.; Simpson, J.F.; Connolly, J.L.; Hayes, D.F.; Edge, S.B.; Lichter, A.; Schnitt, S.J. Archiv. Pathol. Lab. Med., 2000, 124, 966-978.
106. Allred, D.C.; Clark, G.M.; Elledge, R.; Fuqua, S.A.; Brown, R.W.; Chamness, G.C.; Osborne, C.K.; McGuire, W.L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Nat. Cancer Inst., 1993, 85, 200-206.
107. Olivier, M.; Langerød, A.; Carrieri, P.; Bergh, J.; Klaar, S.; Eyfjord, J.; Theillet, C.; Rodriguez, C.; Lidereau, R.; Bièche, I.; Varley, J.; Bignon, Y.; Uhrhammer, N.; Winqvist, R.; Jukkola- Vuorinen, A.; Niederacher, D.; Kato, S.; Ishioka, C.; Hainaut, P.; Børresen-Dale, A.L. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res., 2006, 12, 1157-1167
108. Soerjomataram, I.; Louwman, M.W.; Ribot, J.G.; Roukema, J.A.; Coebergh, J.W. An overview of prognostic factors for long-term survivors of breast cancer. Breast Ca. Res. Treat., 2008, 107, 309- 330.
109. Bozovic-Spasojevic I; Ameye, L.; Paesmans, M.; Larsimont, D.; Di Leo, A.; Dolci, S.; Piccart, M.; de Azambuja, E.; Loi, S. Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. Breast, 2014, 23, 473- 481.
110. Lehmann, B.D.; Pietenpol, J.A. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J. Pathol., 2014, 232, 142-150.
111. Collozza, M.; Azambuja, E.; Cardoso, F.; Sotiriou, C.; Larsimont, D.; Piccart, M.J. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Oncol., 2005, 16, 1723-1739.
112. Finn, R.S.; Crown, J.P.; Lang, I.; Boer, K.;. Bondarenko, I.M.; Kulyk, S.O.; Ettl, J.; Patel, R.; Pinter, T.; Schmidt, M.; Shparyk, Y.V. Thummala, A.R.; Voytko, N.L.; Huang, X.; Kim, S.T.; Randolph, S.S.; Slamon, D.J. Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). Presented at the 2014 AACR Annual Meeting, 2014, abstract CT101.
113. Gewinner, C.; Wang, Z.C.; Richardson, A.; Teruya-Feldstein, J.; Etemadmoghadam, D.; Bowtell, D.; Barretina, J.; Lin, W.M.; Rameh, L.; Salmena, L.; Pandolfi, P.P.; Cantley, L.C. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signalling. Cancer Cell, 2009, 16, 115- 125.
114. Campbell, R.A.; Bhat-Nakshatri, P.; Patel, N.M.; Constantinidou, D.; Ali, S.; Nakshatri, H. Phosphatidylinositol 3-kinase/AKTmediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem., 2001, 276, 9817-9824.
115. Rexer, B.N.; Arteaga, C.L. Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res., 2013, 73, 3817-3820.
116. Chakrabarty, A.; Bhola, N.E.; Sutton, C.; Ghosh, R.; Kuba, M.G.; Dave, B.; Chang, J.C.; Arteaga, C.L. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res., 2013, 73, 1190-1200.
117. Paplomata, E.; O'Regan, R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther. Adv. Med. Oncol., 2014, 6, 154-166.
118. Beaver, J.A.; Gustin, J.P.; Yi, K.H.; Rajpurohit, A.; Thomas, M.; Gilbert, S.F.; Rosen, D.M.; Park, B.H.; Lauring, J. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin. Cancer. Res., 2013, 19, 5413-5422.
119. Giltnane, J.M.; Balko, J.M. Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discov. Med., 2014, 17, 275-283.
120. Pereira, C.B.; Leal, M.F.; de Souza, C.R.; Montenegro, R.C.; Rey, J.A.; Carvalho, A.A.; Assumpção, P.P.; Khayat, A.S.; Pinto, G.R.; Demachki, S.; de Arruda Cardoso Smith, M.; Burbano, R.R. Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. PLoS One, 2013, 8, e60576. doi: 10.1371/journal.pone.0060576.
121. Beelen, K.; Opdam, M.; Severson, T.M.; Koornstra, R.H.; Vincent, A.D.; Wesseling, J.; Muris, J.J.; Berns, E.M.; Vermorken, J.B.; van Diest, P.J.; Linn, S.C. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. Breast Cancer Res., 2014, 16, R6. doi: 10.1186/bcr3598.
122. Hoeflich, K.P.; O'Brien, C.; Boyd, Z.; Cavet, G.; Guerrero, S.; Jung, K.; Januario, T.; Savage, H.; Punnoose, E.; Truong, T.; Zhou, W.; Berry, L.; Murray, L.; Amler, L.; Belvin, M.; Friedman, L.S.; Lackner, M.R. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin. Cancer Res., 2009, 15, 4649-4664.
123. El Touny, L.H.; Vieira, A.; Mendoza, A.; Khanna, C.; Hoenerhoff, M.J.; Green, J.E. Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells. J. Clin. Invest., 2014, 124, 156-168.
124. Fox, S.B.; Generali, D.G.; Harris, A.L. Breast tumour angiogenesis. Breast Cancer Res., 2007, 9, 216. doi:10.1186/bcr1796.
125. Koch, S.; TuGues, S.; Gualandi, L.; Claesson-Welsh, L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J., 2011, 437, 169-183.
126. Kowanetz, M.; Ferrara, N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res., 2006, 12, 5018-5022.
127. Foekens, J.A.; Peters, H.A.; Grebenchtchikov, N.; Look, M.P.; Meijer-van Gelder, M.E.; Geurts-Moespot, A.; van der Kwast, T.H.; Sweep, C.G.; Klijn, J.G.; High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res., 2001, 61, 5407-5414.
128. Fountzilas, G.; Kourea, H.P.; Bobos, M.; Televantou, D.; Kotoula, V.; Papadimitriou, C.; Papazisis, K.T.; Timotheadou, E.; Efstratiou, I.; Koutras, A.; Pentheroudakis, G.; Christodoulou, C.; Aravantinos, G.; Miliaras, D.; Petraki, K.; Papandreou, C.N.; Papakostas, P.; Bafaloukos, D.; Repana, D.; Razis, E.; Pectasides, D.; Dimopoulos, A.M. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res., 2011, 31, 3007-3018.
129. Miles, D.W.; de Haas, S.L.; Dirix, L.Y.; Romieu, G.; Chan, A.; Pivot, X.; Tomczak, P.; Provencher, L.; Cortés, J.; Delmar, P.R.; Scherer, S.J. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br. J. Cancer, 2013, 108, 1052-1106.
130. Sy, S.M.H.; Huen M.S.Y.; Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc. Natl. Acad. Sci USA, 2009, 106, 7155-7160.
131. Poumpouridou, N.; Kroupis, C. Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges. Clin. Chem. Lab. Med., 2011, 50, 423-434.
132. Antoniou, A.C.; Casadei, S.; Heikkinen, T.; Barrowdale, D.; Pylkas, K.; Roberts, J.; Lee, A.; Subramanian, D.; De Leeneer, K.; Fostira, F.; Tomiak, E.; Neuhausen, S.L.; Teo, Z.L.; Khan, S.; Aittomaki, K.; Moilanen, J.S.; Turnbull, C.; Seal, S.; Mannermaa, A.; Kallioniemi, A.; Lindeman, G.J.; Buys, S.S.; Andrulis, I.L.; Radice, P.; Tondini, C.; Manoukian, S.; Toland, A.E.; Miron, P.; Weitzel, J.N.; Domchek, S.M.; Poppe, B.; Claes, K.B.; Yannoukakos, D.; Concannon, P.; Bernstein, J.L.; James, P.A.; Easton, D.F.; Goldgar, D.E.; Hopper, J.L.; Rahman, N.; Peterlongo, P.; Nevanlinna, H.; King, M.C.; Couch, F.J.; Southey, M.C.; Winqvist, R.; Foulkes, W.D.; Tischkowitz, M. Breast-cancer risk in families with mutations in PALB2. New Engl. J. Med., 2014, 371, 497-506.
133. Heikkinen, T.; Karkkainen, H.; Aaltonen, K.; Milne, R.L.; Heikkila, P.; Aittomaki, K.; Blomqvist, C.; Nevanlinna, H. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin. Cancer Res., 2009, 15, 3214- 3222.
134. Southey, M.C.; Teo, Z.L.; Dowty, J.G.; Odefrey, F.A.; Park, D.J.; Tischkowitz, M.; Sabbaghian, N.; Apicella, C.; Byrnes, G.B.; Winship, I.; Baglietto, L.; Giles, G.G.; Goldgar, D.E.; Foulkes, W.D.; Hopper, J.L. A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res., 2010, 12, R109.
135. Widschwendter, M.; Jones, P.A. DNA methylation and breast carcinogenesis. Oncogene, 2002, 21, 5462-5482.
136. Munshi, A.; Shafi, G.; Aliya, N.; Jyothy, A. Histone modifications dictate specific biological readouts. J. Genet. Genomics, 2009, 36, 75-88.
137. Jenuwein, T.; Allis, C.D. Translating the histone code. Science, 2001, 293, 1074-1080.
138. Wade, P.A. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum. Mol. Genet., 2001, 1, 693-698.
139. Elsheikh, S.E.; Green, A.R.; Rakha, E.A.; Powe, D.G.; Ahmed, R.A.; Collins, H.M.; Soria, D.; Garibaldi, J.M.; Paish, C.E.; Ammar, A.A.; Grainge, M.J.; Ball, G.R.; Abdelghany, M.K.; Martinez- Pomares, L.; Heery, D.M.; Ellis, I.O. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res., 2009, 69, 3802-3809.
140. Okano, M.; Bell, D.W.; Haber, D.A.; Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell, 1999, 99, 247-57.
141. Herman, J.G.; Baylin, S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 2003, 349, 2042-2054.
142. Esteller, M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat. Rev. Genet., 2007, 8, 286-298.
143. Pomraning, K.R.; Smith, K.M.; Freitag, M. Genome-wide high throughput analysis of DNA methylation in eukaryotes. Methods, 2009, 47, 142-150.
144. Licchesi, J.D.; Herman, J.G. Methylation-specific PCR. Methods Mol. Biol., 2009, 507, 305-323.
145. Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP. Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod. Pathol., 2003, 16, 1095- 1101.
146. Fackler, M.J.; McVeigh, M.; Evron, E.; Garrett, E.; Mehrotra, J.; Polyak, K.; Sukumar, S.; Argani, P. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int. J. Cancer., 2003, 107, 970- 975.
147. Sebova, K.; Zmetakova, I.; Bella, V.; Kajo, K.; Stankovicova, I.; Kajabova, V.; Krivulcik, T.; Lasabova, Z.; Tomka, M.; Galbavy, S.; Fridrichova, I. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark., 2011, 10, 13- 26.
148. Tserga, A.; Michalopoulos, N.V.; Levidou, G.; Korkolopoulou, P.; Zografos, G.; Patsouris, E.; Saetta, A.A. Association of aberrant DNA methylation with clinicopathological features. Oncol. Rep., 2012, 27, 1630-1638.
149. Turner, N.C.; Reis-Filho, J.S.; Russell. A.M.; Springall, R.J.; Ryder, K.; Steele, D.; Savage, K.; Gillett C.E.; Schmitt, F.C.; Ashworth, A.; Tutt, A.N. BRCA1 dysfunction in sporadic basallike breast cancer. Oncogene, 2007, 26, 2126-2132.
150. Fackler, M.J.; Umbricht, C.B.; Williams, D.; Argani, P.; Cruz, L.A.; Merino, V.F.; Teo, W.W.; Zhang, Z.; Huang, P.; Visvananthan, K.; Marks, J.; Ethier, S.; Gray, J.W.; Wolff, A.C.; Cope, L.M.; Sukumar, S. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res., 2011, 71, 6195-6207.
151. Piekarz, R.L.; Frye, R.; Turner, M.; Wright, J.J.; Allen, S.L.; Kirschbaum, M.H.; Zain, J.; Prince, H.M.; Leonard, J.P.; Geskin, L.J.; Reeder, C.; Joske, D.; Figg, W.D.; Gardner, E.R.; Steinberg, S.M.; Jaffe, E.S.; Stetler-Stevenson, M.; Lade, S.; Fojo, A.T.; Bates, S.E. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol., 2009, 27, 5410-5417.
152. Arts, J.; de Schepper, S.; Van Emelen, K. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr. Med. Chem., 2003, 10, 2343-2350.
153. Connolly, R.; Stearns, V. Epigenetics as a therapeutic target in Breast Cancer. J. Mammary Gland Biol. Neoplasia, 2012, 17, 191- 204.
154. Radpour, R.; Barekati, Z.; Kohler, C.; Schumacher, M.M.; Grussenmeyer, T.; Jenoe, P.; Hartmann, N.; Moes, S.; Letzkus, M.; Bitzer, J.; Lefkovits, I.; Staedtler, F.; Zhong, X.Y. Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment. PLoS ONE, 2011, 6, e27355
155. Fu, S.; Hu, W.; Iyer, R.; Kavanagh, J.J.; Coleman, R.L.; Levenback, C.F.; Sood, A.K.; Wolf, J.K.; Gershenson, D.M.; Markman, M.; Hennessy, B.T.; Kurzrock, R.; Bast, R.C. Jr. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer, 2011, 117, 1661-1669.
156. Munster, P.N.; Troso-Sandoval, T.; Rosen, N.; Rifkind, R.; Marks, P.A.; Richon, V.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res., 2001, 61, 8492-8497.
157. Munster, P.N.; Thurn, K.T.; Thomas, S.; Raha, P.; Lacevic, M.; Miller, A.; Melisko, M.; Ismail-Khan, R.; Rugo, H.; Moasser, M.; Minton, S.E.A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer., 2011, 104, 1828-1835.
158. Connolly, R.M.; Jankowitz, R.C.; Andreopoulou, E.; Allred, J.B.; Jeter, S.C.; Zorzi, J.; Adam, B.M.; Espinoza-Delagado, I.; Baylin, S.B.; Zahnow, C.A.; Ahuja, N.; Davidson, N.E.; Stearns, V. A phase 2 study investigating the safety, efficacy, and surrogate biomarkers or response of 5-azacitidine (5-AZA) and entinostat (MS- 275) in patients with advanced breast cancer. Cancer Res., 2011, 71(24 Suppl. 3): Abstract 4666.
159. Bartel, D.P. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136, 215-233.
160. Fabian, M.R.; Sonenberg, N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRIS. Nat. Struct. Mol. Biol., 2012, 19, 586-593.
161. Saj, A.; Lai, E.C. Control of microRNA biogenesis and transcription by cell signaling pathways. Curr. Opin. Genet. Develop., 2011, 21, 504-510.
162. Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005, 120, 15-20.
163. Friedman, R.; Farh, K.; Burge, C.; Bartel, D. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res., 2009, 19, 92-105.
164. Iorio, M.V.; Croce, C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med., 2012, 4, 143-159.
165. Calin, G.; Croce C. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res., 2006, 66, 7390-7394.
166. Iorio, M.; Ferracin, M.; Liu, C.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M.; Ménar,d S.; Palazzo J.P.; Rosenberg, A.; Musiani, P.; Volinia, S.; Nenci, I.; Calin, G.A.; Querzoli, P.; Negrini, M.; Croce, C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res., 2005, 65, 7065-7070.
167. Blenkiron, C.; Goldstein, L.; Thorne, N.; Spiteri, I.; Chin, S.; Dunning, M.; Barbosa-Morais, N.L.; Teschendorff, A.E.; Green, A.R.; Ellis, I.O.; Tavaré, S.; Caldas, C.; Miska, E.A. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol., 2007, 8, R214
168. Zhu, W.; Qin, W.; Atasoy, U.; Sauter, E. Circulating microRNAs in breast cancer and healthy subjects. BMC Res. Notes, 2009, 2, 89.
169. Heneghan, H.; Miller, N.; Lowery, A.; Sweeney, K.; Newell, J.; Kerin, M. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg., 2010, 251, 499-505.
170. Wu, X.; Somlo, G.; Yu, Y.; Palomares, M.R.; Li, A.X.; Zhou, W.; Chow, A.; Yen, Y.; Rossi, J.J.; Gao, H.; Wang, J.; Yuan, Y-C.; Frankel, P.; Li, S.; Ashing-Giwa,.T.; Sun, G.; Wang, Y.; Smith, R.; Robinson, K.; Ren, X.; Wang S.E. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J. Transl. Med., 2012, 8, 42 doi: 10.1186/1479-5876-8-42.
171. Chen, W.X.; Hu, Q.; Qiu, M.T.; Zhong, S.L.; Xu, J.J.; Tang, J.H.; Zhao, J.H. miR-221/222: promising biomarkers for breast cancer. Tumour Biol., 2013, 34, 1361-70.
172. Mei, M.; Ren, Y.; Zhou, X.; Yuan. X.; Han. L.; Wang. G.; Jia, Z.; Pu, P.Y.; Kang, C.S.; Yao, Z. Downregulation of mir-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol. Cancer Res. Treat., 2010, 9, 77-86.
173. Gong, C.; Yao, Y.; Wang, Y.; Liu, B.; Wu, W.; Chen, J.; Su, F.; Yao, H.; Song, E. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem., 2011, 286, 19127-19137.
174. Iorio, M.; Casalini, P.; Piovan, C.; Di Leva, G.; Merlo, A.; Triulzi, T.; Ménard, S.; Croce, C.M.; Tagliabue, E. MicroRNA-205 regulates her3 in human breast cancer. Cancer Res., 2009, 69, 2195- 2200.
175. Serpico, D.; Molino, L.; Cosimo S.D. MicroRNAs in breast cancer development and treatment. Cancer Treat. Rev., 2014, 40, 595-604.
176. Salgado, R.; Denkert, C.; Demaria, S., Sirtaine, N.; Klauschen, F.; Pruneri, G.; Wienert, S.;, Van den Eynden, G.; Baehne, F.L.; Penault-Llorca, F.; Perez, E.A.; Thompson, E.A.; Symmans, W.F.; Richardson, A.L.; Brock, J.; Criscitiello, C.; Bailey, H.; Ignatiadis, M.; Floris, G.; Sparano, J.; Kos, Z.; Nielsen, T.; Rimm, D.L.; Allison, K.H.; Reis-Filho, J.S.; Loibl, S.; Sotiriou, C.; Viale, G.; Badve, S.; Adams, S.; Willard-Gallo, K.; Loi, S. Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014. Ann. Oncol., 2014 Sep 11. pii: mdu450. [Epub ahead of print]